As prevalence of CVDs continues to increase, the AHA and AMA have developed the Target BP initiative to improve blood ...

On an overcast Tuesday in December, Michael Hale stood before a group of students at the Portland Opportunities Industrial ...

In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this ...

Chinese scientists have found a common hypertension drug could prove potent in treating a rare but highly invasive brain ...

Steve Van Wormer has published nearly 500 podcasts about pulmonary hypertension (PH) — more than perhaps anyone working in rare diseases.

The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair ...

PAH, or pulmonary hypertension, can leave someone breathless even after a short walk, but better drug combinations have ...

Pulmonary arterial hypertension (PAH) affected an estimated 192,000 individuals globally in 2021, disproportionately affecting women and older adults.

Out of 1.66 crore people aged 30 and above in Telangana, 22.94 lakh suffer from hypertension, while 11.9 lakh have diabetes, ...

Glaucoma, the leading cause of blindness, is often marked by loss of retinal ganglion cells (RGCs). Necroptosis, a form of ...